Esther Rajavelu - Nov 7, 2025 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Chief Executive Officer, Chief Financial Officer and Chief Business Officer
Signature
/s/ Maegan Deare, Attorney-in-Fact for Esther Rajavelu
Stock symbol
SPRO
Transactions as of
Nov 7, 2025
Transactions value $
-$95,440
Form type
4
Date filed
11/12/2025, 08:44 PM
Previous filing
May 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rajavelu Esther Chief Executive Officer, Chief Financial Officer and Chief Business Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE /s/ Maegan Deare, Attorney-in-Fact for Esther Rajavelu 2025-11-12 0001903716

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Sale -$95.4K -40.3K -4.43% $2.37 869K Nov 7, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on November 13, 2023.

Remarks:

Chief Executive Officer, Chief Financial Officer and Chief Business Officer